EMAIL THIS PAGE TO A FRIEND

The Journal of neuroscience : the official journal of the Society for Neuroscience

Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.


PMID 25164669

Abstract

The dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) is widely used as a therapeutic choice for the treatment of patients with Parkinson's disease. However, the long-term use of L-DOPA leads to the development of debilitating involuntary movements, called L-DOPA-induced dyskinesia (LID). The cAMP/protein kinase A (PKA) signaling in the striatum is known to play a role in LID. However, from among the nine known adenylyl cyclases (ACs) present in the striatum, the AC that mediates LID remains unknown. To address this issue, we prepared an animal model with unilateral 6-hydroxydopamine lesions in the substantia nigra in wild-type and AC5-knock-out (KO) mice, and examined behavioral responses to short-term or long-term treatment with L-DOPA. Compared with the behavioral responses of wild-type mice, LID was profoundly reduced in AC5-KO mice. The behavioral protection of long-term treatment with L-DOPA in AC5-KO mice was preceded by a decrease in the phosphorylation levels of PKA substrates ERK (extracellular signal-regulated kinase) 1/2, MSK1 (mitogen- and stress-activated protein kinase 1), and histone H3, levels of which were all increased in the lesioned striatum of wild-type mice. Consistently, FosB/ΔFosB expression, which was induced by long-term L-DOPA treatment in the lesioned striatum, was also decreased in AC5-KO mice. Moreover, suppression of AC5 in the dorsal striatum with lentivirus-shRNA-AC5 was sufficient to attenuate LID, suggesting that the AC5-regulated signaling cascade in the striatum mediates LID. These results identify the AC5/cAMP system in the dorsal striatum as a therapeutic target for the treatment of LID in patients with Parkinson's disease.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

D9628
3,4-Dihydroxy-L-phenylalanine, ≥98% (TLC)
C9H11NO4
H8523
6-Hydroxydopamine hydrobromide, ≥90% (HPLC), solid
C8H11NO3 · HBr
H116
6-Hydroxydopamine hydrobromide, contains ascorbic acid as stabilizer, ≥98% (HPLC)
C8H11NO3 · HBr
162957
6-Hydroxydopamine hydrobromide, 95%
C8H11NO3 · HBr
MAB1501
Anti-Actin Antibody, clone C4, 100 µL, Reliably and specifically detect actin using this Anti-Actin Antibody, clone C4. This highly published monoclonal antibody is validated for use in ELISA, IC, IF, IH, IH(P) & WB. This mAb is also available as a fluorescent conjugate.
04-823
Anti-phospho-GluR1 (Ser831) Antibody, clone N453, rabbit monoclonal, 100 µL, Anti-phospho-GluR1 (Ser831) Antibody, clone N453 detects level of phospho-GluR1 (Ser831) & has been published & validated for use in WB.
05-1315
Anti-phospho (Ser10) acetyl (Lys14) Histone H3 Antibody, clone 10H10.2, 100 µg, Use Anti-phospho (Ser10) acetyl (Lys14) Histone H3 Antibody, clone 10H10.2 (Mouse Monoclonal Antibody) validated in WB to detect phospho (Ser10) acetyl (Lys14) Histone H3 also known as H3S10PK14Ac.
SAB4504041
Anti-phospho-MSK1 (pThr581) antibody produced in rabbit, affinity isolated antibody
L0400000
Levodopa, European Pharmacopoeia (EP) Reference Standard
C9H11NO4
1361009
Levodopa, United States Pharmacopeia (USP) Reference Standard
C9H11NO4
PHR1271
Levodopa, Pharmaceutical Secondary Standard; Certified Reference Material
C9H11NO4